Protocol Ledger

NCT06456346 · Phase III · ACTIVE NOT RECRUITING

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Interventional Phase III clinical trial protocol NCT06456346 sponsored by Merck & Co. in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-16 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06456346
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06456346
Protocol FieldVerified Registry Value
NCT IdentifierNCT06456346
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2024-07-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI